599 related articles for article (PubMed ID: 36726464)
1. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD).
Rong L; Zou J; Ran W; Qi X; Chen Y; Cui H; Guo J
Front Endocrinol (Lausanne); 2022; 13():1087260. PubMed ID: 36726464
[TBL] [Abstract][Full Text] [Related]
2. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.
Clemente MG; Mandato C; Poeta M; Vajro P
World J Gastroenterol; 2016 Sep; 22(36):8078-93. PubMed ID: 27688650
[TBL] [Abstract][Full Text] [Related]
3. NAFLD: Mechanisms, Treatments, and Biomarkers.
Nassir F
Biomolecules; 2022 Jun; 12(6):. PubMed ID: 35740949
[TBL] [Abstract][Full Text] [Related]
4. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
5. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease.
Negi CK; Babica P; Bajard L; Bienertova-Vasku J; Tarantino G
Metabolism; 2022 Jan; 126():154925. PubMed ID: 34740573
[TBL] [Abstract][Full Text] [Related]
6. Phytotherapy as Multi-Hit Therapy to Confront the Multiple Pathophysiology in Non-Alcoholic Fatty Liver Disease: A Systematic Review of Experimental Interventions.
Ore A; Akinloye OA
Medicina (Kaunas); 2021 Aug; 57(8):. PubMed ID: 34441028
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes.
Hydes TJ; Summers N; Brown E; Alam U; Thomaides-Brears H; Wilding JPH; Cuthbertson DJ
Diabet Med; 2020 Nov; 37(11):1793-1806. PubMed ID: 32619031
[TBL] [Abstract][Full Text] [Related]
8. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease.
Brown E; Hydes T; Hamid A; Cuthbertson DJ
Clin Ther; 2021 Sep; 43(9):1476-1504. PubMed ID: 34446271
[TBL] [Abstract][Full Text] [Related]
9. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.
Miura K; Ohnishi H
World J Gastroenterol; 2014 Jun; 20(23):7381-91. PubMed ID: 24966608
[TBL] [Abstract][Full Text] [Related]
10. Progress in the Treatment of Metabolic-Related Fatty Liver Disease.
Zhang B; Feng Y; Lu J
Altern Ther Health Med; 2023 Oct; 29(7):86-93. PubMed ID: 37535913
[TBL] [Abstract][Full Text] [Related]
11. Physical exercise plays a role in rebalancing the bile acids of enterohepatic axis in non-alcoholic fatty liver disease.
Zhang M; Xiao B; Chen X; Ou B; Wang S
Acta Physiol (Oxf); 2024 Jan; 240(1):e14065. PubMed ID: 38037846
[TBL] [Abstract][Full Text] [Related]
12. Nutritional and Lifestyle Therapy for NAFLD in People with HIV.
Cinque F; Cespiati A; Lombardi R; Guaraldi G; Sebastiani G
Nutrients; 2023 Apr; 15(8):. PubMed ID: 37111209
[TBL] [Abstract][Full Text] [Related]
13. Obesity and Nonalcoholic Fatty Liver Disease.
Chaney A
Nurs Clin North Am; 2021 Dec; 56(4):543-552. PubMed ID: 34749893
[TBL] [Abstract][Full Text] [Related]
14. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
[TBL] [Abstract][Full Text] [Related]
15. Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome.
Abenavoli L; Scarlata GGM; Scarpellini E; Boccuto L; Spagnuolo R; Tilocca B; Roncada P; Luzza F
Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984595
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice.
Zhou ST; Cui W; Kong L; Yang X
Curr Med Sci; 2022 Jun; 42(3):513-519. PubMed ID: 35451807
[TBL] [Abstract][Full Text] [Related]
17. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.
Kirpich IA; Marsano LS; McClain CJ
Clin Biochem; 2015 Sep; 48(13-14):923-30. PubMed ID: 26151226
[TBL] [Abstract][Full Text] [Related]
18. Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota.
Drożdż K; Nabrdalik K; Hajzler W; Kwiendacz H; Gumprecht J; Lip GYH
Nutrients; 2021 Dec; 14(1):. PubMed ID: 35010976
[TBL] [Abstract][Full Text] [Related]
19. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
Xie C; Halegoua-DeMarzio D
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
[TBL] [Abstract][Full Text] [Related]
20. Current insights in molecular characterization of non-alcoholic fatty liver disease and treatment.
Che W; Zhao M; Li X; Li C; Cho WC; Yu S
Front Endocrinol (Lausanne); 2022; 13():1002916. PubMed ID: 36523601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]